|
Variable
|
5-year CSS rate (%, 95% CI)
|
|---|
|
Training cohort
|
P value
|
External validation cohort
|
P value
|
|---|
|
T stage
| |
< 0.001
| |
< 0.001
|
|
≤ T1a
|
87.5 (81.0–94.0)
|
94.6 (90.0–99.1)
|
|
T2
|
63.0 (51.0–75.0)
|
75.3 (66.5–84.1)
|
|
T3
|
56.2 (42.7–69.7)
|
70.1 (61.7–78.5)
|
|
T4
|
13.0 (0–33.8)
|
11.1 (0–31.7)
|
|
N stage
| |
< 0.001
| |
< 0.001
|
|
N0
|
94.3 (90.8–97.8)
|
90.8 (87.3–94.3)
|
|
N1
|
68.0 (50.6–85.4)
|
55.7 (29.2–82.2)
|
|
N2
|
9.5 (0–21.8)
|
12.9 (0–29.4)
|
|
N3
|
0
| |
0
|
|
M stage
| |
< 0.001
| |
< 0.001
|
|
M0
|
69.9 (63.8–76.0)
|
79.6 (75.1–84.1)
|
|
M1
|
0
|
0
|
|
Pathological grade
| |
< 0.001
| |
0.002
|
|
G1–2
|
71.6 (65.5–83.8)
|
81.4 (76.3–86.5)
|
|
G3
|
18.7 (0–47.7)
|
69.8 (60.2–79.4)
|
|
Lymphovascular embolization
| |
< 0.001
| |
< 0.001
|
|
Yes
|
30.8 (15.9–45.7)
|
50.0 (38.8–61.2)
|
|
No
|
77.0 (70.9–77.0)
|
86.5 (82.2–90.8)
|
|
Perineural invasion
| |
< 0.001
| |
0.010
|
|
Yes
|
40.3 (23.6–57.0)
|
65.7 (52.0–79.4)
|
|
No
|
73.3 (67.0–79.6)
|
80.5 (75.8–85.2)
|
|
Modified staging system
| |
< 0.001
| |
< 0.001
|
|
≤ t1b
|
87.5 (81.0–94.0)
|
94.6 (90.0–99.1)
|
|
t2
|
69.2 (59.2–89.2)
|
82.5 (76.4–88.6)
|
|
t3
|
33.4 (16.5–50.3)
|
42.9 (29.2–56.6)
|
|
t4
|
13.0 (0–33.8)
|
11.1 (0–31.7)
|
- CI confidence interval
- a≤ T1 includes T0, Tis, Ta, and T1
- b≤ t1 includes t0, tis, ta, and t1
